The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
ApexOnco Front Page
Recent articles
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
The disappointing Pynnacle trial is set to yield registrational data.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
A single but durable stable disease sends the microcap's stock up 730%.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
A newly published cache of CRLs includes six novel oncology drugs.
